Mertansine (GMP)
Mertansine (GMP) is the GMP-grade version of Mertansine (HY-19792). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC).
For research use only. We do not sell to patients.
- CAS No.: 139504-50-0
- Formula: C35H48ClN3O10S
- Molecular Weight:738.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
Maytansinoids |
In Vitro
Mertansine is a strong antiproliferative chemotherapeutics toward over 60 types of cancer cell lines[3].
Mertansine (0-1 μg/mL) shows antitumor activity in malignant B16F10 melanoma cells, and inhibits tumor cell growth by inhibiting mitosis when combined with DTX[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Malignant B16F10 melanoma cells[3]
-
Concentration:0, 0.01, 0.1, and 1 μg/mL
-
Incubation Time:4 h
-
Result:Showed antitumor activity in malignant B16F10 melanoma cells, with an IC50 of 0.092 μg/mL. Co-delivery of DTX and DM1, both of which inhibit tumor cell growth by inhibiting mitosis, is an effective strategy to achieve a combinatorial anticancer effect.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 139504-50-0
-
Molecular Weight 738.29
-
Formula C35H48ClN3O10S
-
SMILES
C[C@]1([C@@](CC(N(C(C=C2C=C3OC)=C3Cl)C)=O)([H])OC([C@H](C)N(C)C(CCS)=O)=O)[C@H]([C@@H]([C@](OC4=O)([H])C[C@]([C@](/C=C/C=C(C)/C2)([H])OC)(N4)O)C)O1
-
Synonyms
DM1 (GMP); Maytansinoid DM1 (GMP)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subchronic/Chronic Toxicity Study
A subchronic/chronic oral toxicity study detects systemic adverse effects caused by repeated administration of a test article, using mortality, clinical signs, body weight, food/water intake, ophthalmology, urinalysis, hematology, serum biochemistry, organ weights, gross necropsy, and histopathology as integrated readouts. The readout reflects dose-related physiological injury, target-organ pathology, reversibility after recovery, and derivation of NOAEL, LOAEL, or related point-of-departure values when the dataset supports them.
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
Purity & Documentation
References
[1]. Manu Lopus et al. Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules. [Content Brief]
[2]. Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 2011 Aug 28;307(2):113-8. [Content Brief]
[3]. Zhong P, et al. cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. Nanotechnology. 2017 Jul 21;28(29):295103. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)